Findings showed treatment with Xhance was associated with a statistically significant improvement on both study endpoints compared with placebo. The Food and Drug Administration (FDA) has approved ...

Xhance (fluticasone propionate) is a brand-name drug that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance comes as a nasal spray that’s typically used twice per ...

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...

ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million. Triggering the ...

LOS ANGELES (KABC) -- One in eight U.S. adults struggle to breathe and battle the persistent pain and discomfort of chronic sinusitis. Even with sprays, irrigations and pills, a staggering 80% of ...

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If ...

Xhance (fluticasone propionate) is a brand-name nasal spray that’s prescribed for chronic rhinosinusitis with or without nasal polyps in adults. Xhance has interactions with some other drugs, such as ...

YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...

The FDA expanded the approval of fluticasone propionate (Xhance) nasal spray for chronic rhinosinusitis to also include treatment of adults without nasal polyps, manufacturer Optinose announced on ...